{"id":688631,"date":"2022-09-26T07:16:00","date_gmt":"2022-09-26T11:16:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"modified":"2022-09-26T07:16:00","modified_gmt":"2022-09-26T11:16:00","slug":"oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","title":{"rendered":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ANDOVER, Mass., Sept.  26, 2022  (GLOBE NEWSWIRE) &#8212; Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan\u2019s 6<sup>th<\/sup> Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY.<\/p>\n<p>A live webcast of the fireside chat can be accessed by visiting the Investors &amp; Media section of Oncorus\u2019 website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EnON7xPTwKFm6LPfi2xKfjLj_92EZwG4g65i5V2NgAABPy1z2ADXKLSaJBbHKtrd7TmoQzPD8Pb-4ZMybs9v9wT0oxCXgPXmIGL0lU9uUrKjDBoD-y7_PuOPPQEEOjZQ\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.oncorus.com\/<\/a>. A replay of the webcast will be archived on Oncorus\u2019 website for 90 days following the event.<\/p>\n<p>\n        <strong>About Oncorus<\/strong>\n      <\/p>\n<p>At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) and self-amplifying viral RNA Immunotherapy Platforms.<\/p>\n<p>Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering self-amplifying vRNA Immunotherapy Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer.<\/p>\n<p>Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3ebeHXJAQupHIqI-c0QQUENIC-1_IMhBf3stI7uUm2IrGY0toUePdgobUwqbliDJ_4BwIoU8Pv6vWyuv5GQJRw==\" rel=\"nofollow noopener\" target=\"_blank\">www.oncorus.com<\/a> to learn more.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>\n        <strong>Stern Investor Relations<\/strong><br \/>\n        <br \/>Julie Seidel<br \/>Julie.seidel@sternir.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjhjMjE2N2YtYjFjZC00OWExLWJiMWEtYTI5ZjYyMzIyNGRjLTEyMTI5OTc=\/tiny\/Oncorus-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be accessed by visiting the Investors &amp; Media section of Oncorus\u2019 website at\u00a0https:\/\/investors.oncorus.com\/. A replay of the webcast will be archived on Oncorus\u2019 website for 90 days following the event. About Oncorus At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be accessed by visiting the Investors &amp; Media section of Oncorus\u2019 website at\u00a0https:\/\/investors.oncorus.com\/. A replay of the webcast will be archived on Oncorus\u2019 website for 90 days following the event. About Oncorus At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform &hellip; Continue reading &quot;Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T11:16:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\",\"datePublished\":\"2022-09-26T11:16:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"name\":\"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\",\"datePublished\":\"2022-09-26T11:16:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","og_description":"ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be accessed by visiting the Investors &amp; Media section of Oncorus\u2019 website at\u00a0https:\/\/investors.oncorus.com\/. A replay of the webcast will be archived on Oncorus\u2019 website for 90 days following the event. About Oncorus At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform &hellip; Continue reading \"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T11:16:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference","datePublished":"2022-09-26T11:16:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","name":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=","datePublished":"2022-09-26T11:16:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg4NiM1MTY3Njk0IzIyMDE0NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncorus-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncorus to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}